Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew ...

Consensus directed medical therapy (CDMT) was used in 73.1% of DMD patients with moderate or severe left ventricular dysfunction, leaving nearly 30% without recommended treatment. Target doses were ...

The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment's ability to help ...

Catalyst is offering patients and their caregivers a personalized program called Catalyst Pathways to provide guidance and financial support. Agamree ® (vamorolone) oral suspension has been made ...

—Starting cardiac medications, using the proper timing and dosing, to optimize the efficacy of therapies and improve patient outcomes, is key to cardiac care for patients with Duchenne muscular ...

Credit: Italfarmaco. The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 EPIDYS study. Duvyzat is the first nonsteroidal treatment approved for patients with ...

DUBLIN--(BUSINESS WIRE)--The "Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Duchenne Muscular ...

Experts discuss the landscape of treatment options for Duchenne muscular dystrophy, examine the benefits and risks of gene therapy and conventional steroid treatments, and emphasize the need for early ...

The FDA has approved Duvyzat for the treatment of Duchenne muscular dystrophy among patients aged 6 years and older, according to a press release. Duvyzat (givinostat, Italfarmaco) is a histone ...

Dyne Therapeutics’ experimental treatment for Duchenne muscular dystrophy (DMD) showed promise in new data from a small Phase 1/2 trial dubbed DELIVER, the pharma announced this week. The drug, ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Muscular dystrophy, as a category, is quite ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.